title: [Therapeutic options for autoimmune encephalomyelitis].
abstract: Autoantibodies to neuronal tissue are becoming increasingly more important in the evaluation and classification of several neurological diseases, e.g. neuromyelitis optica, paraneoplastic syndromes of the central nervous system (CNS), stiff person syndrome or autoimmune epilepsy. As these disorders are rare, no evidence-based recommendations for therapy are available. Currently, immunomodulating or immunosuppressive drugs are administered in most cases. In paraneoplastic syndromes treatment of the underlying cancer is of considerable importance. This overview summarizes current experiences and recommendations in the treatment of autoimmune neurological disorders.
authors.affiliation: NeuroCure Clinical Research Center und Clinical and Experimental Research Center, Charité - Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Deutschland. nadja.borisow@charite.de
authors.forename: N
authors.initials: N
authors.lastname: Borisow
authors.forename: H
authors.initials: H
authors.lastname: Prüss
authors.forename: F
authors.initials: F
authors.lastname: Paul
mesh_terms: D001323:Autoantibodies / Q000276:immunology*; D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy* / Q000276:immunology*; D004679:Encephalomyelitis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy / Q000639:trends
chemical_list: D001323:Autoantibodies; D007155:Immunologic Factors; D007166:Immunosuppressive Agents